Skip to main content
SpringerLink
Log in

Chronomics of the Metabolic Syndrome

  • Chapter
The Metabolic Syndrome

Part of the book series: Contemporary Endocrinology ((COE))

Abstract

Wars are raging over the definition of the metabolic syndrome—and whether it even exists or is a useful concept. Looking closely at the various viewpoints concerning the definition of the syndrome, one comes to the inescapable conclusion that they are all right! Although some would equate this defining of the syndrome to the efforts of the six men of Industan (who to learning were much inclined), others would cry, “The Emperor has no clothes!” Still others would see it as Stone Soup, gathering ingredients from hither and yon. Let us hope instead that we have provided Soup for the Soul and rekindled your interest in this, the most prevalent of syndromes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Nestel P. Metabolic syndrome: Multiple candidate genes, multiple environmental factors—multiple syndromes? Int J Clin Pract Suppl 2003; 134:3–9.

    CAS  PubMed  Google Scholar 

  2. Kahn R et al. The metabolic syndrome—time for a critical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28(9):2289–2304.

    Article  PubMed  Google Scholar 

  3. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications: Part 1. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15(7):539–553.

    Article  CAS  PubMed  Google Scholar 

  4. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation: European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999: 16(5):442–443.

    Article  CAS  PubMed  Google Scholar 

  5. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285(19):2486–2497.

    Google Scholar 

  6. Einhorn D et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003; 9(3):237–252.

    PubMed  Google Scholar 

  7. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome—a new world-wide definition: A consensus statement from the International Diabetes Federation. Diabet Med 2006; 23(5):469–480.

    Article  CAS  PubMed  Google Scholar 

  8. Grundy SM et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005; 112(17):2735–2752.

    Article  PubMed  Google Scholar 

  9. Zimmet P et al. The metabolic syndrome: A global public health problem and a new definition. J Atheroscler Thromb 2005; 12(6):295–300.

    CAS  PubMed  Google Scholar 

  10. Grundy SM et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation, 2004; 109(3):433–438.

    Article  PubMed  Google Scholar 

  11. Cheal KL et al. Relationship to insulin resistance of the Adult Treatment Panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes 2004; 53(5):1195–1200.

    Article  CAS  PubMed  Google Scholar 

  12. Liao Y et al. Critical evaluation of Adult Treatment Panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care 2004; 27(4):978–983.

    Article  PubMed  Google Scholar 

  13. Zimmet P, MM Alberti KG, Serrano Rios M. A new International Diabetes Federation worldwide definition of the metabolic syndrome: The rationale and the results. Rev Esp Cardiol 2005; 58(12):1371–1376.

    Article  PubMed  Google Scholar 

  14. Meigs JB et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 2006; 91(8):2906–2912.

    Article  CAS  PubMed  Google Scholar 

  15. Reaven GM. Banting lecture 1988: Role of insulin resistance in human disease. Diabetes 1988; 37(12):1595–1607.

    Article  CAS  PubMed  Google Scholar 

  16. Wilson PW et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112(20):3066–3072.

    Article  CAS  PubMed  Google Scholar 

  17. Costa LA et al. Aggregation of features of the metabolic syndrome is associated with increased prevalence of chronic complications in Type 2 diabetes. Diabet Med 2004; 21(3):252–255.

    Article  CAS  PubMed  Google Scholar 

  18. Bonora E et al. The metabolic syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects: Prospective data from the Verona Diabetes Complications Study. Diabet Med 2004; 21(1):52–58.

    Article  Google Scholar 

  19. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 2004; 27(10):2444–2449.

    Article  PubMed  Google Scholar 

  20. Camus JP. [Gout, diabetes, hyperlipemia: A metabolic trisyndrome.] Rev Rhum Mal Osteoartic 1966; 33(1):10–14.

    CAS  PubMed  Google Scholar 

  21. Crepaldi G, Nosadini R. Diabetic cardiopathy: Is it a real entity? Diabetes Metab Rev 1988; 4(3):273–288.

    Article  CAS  PubMed  Google Scholar 

  22. DeFronzo RA, Ferrannini E. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14(3):173–194.

    Article  CAS  PubMed  Google Scholar 

  23. Eriksson J, Taimela S, Koivisto VA. Exercise and the metabolic syndrome. Diabetologia 1997; 40(2):125–135.

    Article  CAS  PubMed  Google Scholar 

  24. Kaplan NM. The deadly quartet: Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989; 149(7):1514–1520.

    Article  CAS  PubMed  Google Scholar 

  25. Scott R et al. Will acarbose improve the metabolic abnormalities of insulin-resistant type 2 diabetes mellitus? Diab Res Clin Pract 1999 Mar; 43(3):179–185.

    Article  CAS  Google Scholar 

  26. Shafrir E. Animal models of syndrome X. Curr Top Diab Res 1993; 12:165–181.

    CAS  Google Scholar 

  27. Zimmet P. The epidemiology of diabetes mellitus and related conditions. In: The Diabetes Annual/6, Alberti K, Krall LP (eds.), 1991, Elsevier, Amsterdam.

    Google Scholar 

  28. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005; 28(11):2745–2749.

    Article  PubMed  Google Scholar 

  29. Ford ES. Rarer than a blue moon: The use of a diagnostic code for the metabolic syndrome in the U.S. Diabetes Care 2005; 28(7):1808–1809.

    Article  PubMed  Google Scholar 

  30. Alexander CM. The coming of age of the metabolic syndrome. Diabetes Care 2003; 26(11):3180–3181.

    Article  Google Scholar 

  31. Grundy SM. Does a diagnosis of metabolic syndrome have value in clinical practice? Am J Clin Nutr 2006; 83(6):1248–1251.

    CAS  PubMed  Google Scholar 

  32. Gotto AM Jr et al. The metabolic syndrome: A call to action. Coron Artery Dis 2006; 17(1):77–80.

    Article  PubMed  Google Scholar 

  33. Bray GA. Obesity is a chronic, relapsing neurochemical disease. Int JObes Relat Metab Disord 2004; 28(1):34–38.

    Article  CAS  Google Scholar 

  34. Bonnet F et al. Waist circumference and the metabolic syndrome predict the development of elevated albuminuria in non-diabetic subjects: The DESIR Study. J Hypertens 2006; 24(6):1157–1163.

    Article  Google Scholar 

  35. Carr DB et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004; 53(8):2087–2094.

    Article  CAS  PubMed  Google Scholar 

  36. Deen D. Metabolic syndrome: Time for action. Am Fam Physician 2004; 69(12):2875–2882.

    PubMed  Google Scholar 

  37. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: A summary of the evidence. Diabetes Care 2005; 28(7):1769–1778.

    Article  PubMed  Google Scholar 

  38. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2004; 89(6):2595–2600.

    Article  CAS  PubMed  Google Scholar 

  39. Kahn SE et al. Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes. Diabetes 2006; 55(8):2357–2364.

    Article  CAS  PubMed  Google Scholar 

  40. Wang YY et al. Association between hematological parameters and metabolic syndrome components in a Chinese population. J Diab Compl 2004: 18(6):322–327.

    Article  Google Scholar 

  41. Corsetti JP et al. Metabolic syndrome best defines the multivariate distribution of blood variables in postinfarction patients. Atherosclerosis 2003; 171(2):351–358.

    Article  CAS  PubMed  Google Scholar 

  42. Sowers JR. Recommendations for special populations: Diabetes mellitus and the metabolic syndrome. Am J Hypertens 2003; 16(11, pt. 2):41S–45S.

    Article  PubMed  Google Scholar 

  43. Chan JC et al. The central roles of obesity-associated dyslipidaemia, endothelial activation and cytokines in the Metabolic Syndrome-an analysis by structural equation modelling. Int J Obes Relat Metab Disord 2002; 26(7):994–1008.

    Article  CAS  PubMed  Google Scholar 

  44. Herder C et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: Results from the Finnish Diabetes Prevention Study. Diabetes 2006; 55(8):2340–2346.

    Article  CAS  PubMed  Google Scholar 

  45. Schneider JG et al. The metabolic syndrome in women. Cardiol Rev 2006; 14(6):286–291.

    Article  PubMed  Google Scholar 

  46. Reaven GM. The metabolic syndrome: Is this diagnosis necessary? Am J Clin Nutr 2006; 83(6):1237–1247.

    CAS  PubMed  Google Scholar 

  47. Koerker DJ et al. Synchronous sustained oscillations of C-peptide and insulin in the plasma of fasting monkeys. Endocrinology 1978; 102:1649–1652.

    Article  CAS  PubMed  Google Scholar 

  48. Hansen BC et al. Neural influences on oscillations in basal plasma levels of insulin in monkeys. Am J Physiol (Endocrinol Metab 1) 1981; 240:E5–E11.

    CAS  Google Scholar 

  49. Hansen BC et al. Rapid oscillations in plasma insulin, glucagon, and glucose in obese and normal weight humans. J Clin Endocrinol Metab 1982; 54:785–792.

    Article  CAS  PubMed  Google Scholar 

  50. Seeley RJ, Tschop M. How diabetes went to our heads. Nat Med 2006; 12(1):47–49; discussion at 49.

    Article  CAS  PubMed  Google Scholar 

  51. Kaufman D et al. Early appearance of the metabolic syndrome in socially reared bonnet macaques. J Clin Endocrinol Metab 2005; 90(1):404–408.

    Article  CAS  PubMed  Google Scholar 

  52. Junien C et al. [Nutritional epigenomics of metabolic syndrome.] Med Sci (Paris) 2005; 21(spec. no.):44–52.

    Google Scholar 

  53. Weyer C et al. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104(6):787–794.

    Article  CAS  PubMed  Google Scholar 

  54. Lorenzo C et al. The metabolic syndrome as predictor of type 2 diabetes: The San Antonio heart study. Diabetes Care 2003; 26(11):3153–3159.

    Article  PubMed  Google Scholar 

  55. Lorenzo C et al. Geographic variations of the International Diabetes Federation and the National Cholesterol Education Program-Adult Treatment Panel III definitions of the metabolic syndrome in nondiabetic subjects. Diabetes Care 2006; 29(3):685–691.

    Article  PubMed  Google Scholar 

  56. Lorenzo C et al. Trend in the prevalence of the metabolic syndrome and its impact on cardiovascular disease incidence: The San Antonio Heart Study. Diabetes Care 2006; 29(3):625–630.

    Article  PubMed  Google Scholar 

  57. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106(25):3143–3421.

    Google Scholar 

  58. Aguilar-Salinas CA et al. Design and validation of a population-based definition of the metabolic syndrome. Diabetes Care 2006; 29(11):2420–2426.

    Article  PubMed  Google Scholar 

  59. Ludwig DS, Ebbeling CB. Type 2 diabetes mellitus in children: Primary care and public health considerations. JAMA 2001; 286(12):1427–1430.

    Article  CAS  PubMed  Google Scholar 

  60. Golley RK et al. Comparison of metabolic syndrome prevalence using six different definitions in overweight pre-pubertal children enrolled in a weight management study. Int JObes (Lond) 2006; 30(5):853–860.

    Article  CAS  Google Scholar 

  61. Grundy SM et al. Clinical management of metabolic syndrome: Report of the American Heart Associationl/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004; 109(4):551–556.

    Article  PubMed  Google Scholar 

  62. Knowler WC et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346(6):393–403.

    Article  CAS  PubMed  Google Scholar 

  63. Sacks FM et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet: DASH-Sodium Collaborative Research Group. N Engl J Med 2001; 344(1):3–10.

    Article  CAS  PubMed  Google Scholar 

  64. Sahyoun NR et al. Whole-grain intake is inversely associated with the metabolic syndrome and mortality in older adults. Am J Clin Nutr 2006; 83(1):124–131.

    CAS  PubMed  Google Scholar 

  65. Grundy SM, Abate N, Chandalia M. Diet composition and the metabolic syndrome: What is the optimal fat intake? Am J Med 2002; 113(suppl 9B):25S–29S.

    Article  CAS  PubMed  Google Scholar 

  66. Trichopoulou A et al. Adherence to a Mediterranean diet and survival in a Greek population. N Engl J Med 2003; 348(26):2599–2608.

    Article  PubMed  Google Scholar 

  67. Foster GD et al. A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med 2003; 348(21):2082–2090.

    Article  CAS  PubMed  Google Scholar 

  68. Van Gaal LF et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: l-year experience from the RIO-Europe study. Lancet 2005; 365(9468):1389–1397.

    Article  PubMed  Google Scholar 

  69. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353(20):2121–2134.

    Article  CAS  PubMed  Google Scholar 

  70. Pi-Sunyer FX et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America—a randomized controlled trial. JAMA 2006; 295(7):761–775.

    Article  CAS  PubMed  Google Scholar 

  71. Nissen SE et al. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: Two randomized controlled trials. JAMA 2007; 297(12): 1362–1373.

    Article  CAS  PubMed  Google Scholar 

  72. Sauerberg P et al. Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo. J Med Chem 2007; 50(7):1495–1503.

    Article  CAS  PubMed  Google Scholar 

  73. Goldstein BJ et al. Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: A 12-week dose-ranging trial. Curr Med Res Opin 2006; 22(12):2575–2590.

    Article  CAS  PubMed  Google Scholar 

  74. Gonzalez IC et al. Design and synthesis of a novel class of dual PPARgamma/delta agonists. Bioorg Med Chern Lett 2007; 17(4):1052–1055.

    Article  CAS  Google Scholar 

  75. Bodkin NL, Hansen BC. Prevention of Syndrome X by long-term dietary restriction (DR) in aged rhesus monkeys. In: The Gerontologist, 1995.

    Google Scholar 

  76. Ortmeyer HK, Bodkin NL, Hansen BC. Chronic caloric restriction alters glycogen metabolism in rhesus monkeys. Obes Res 1994; 2:549–555.

    CAS  PubMed  Google Scholar 

  77. DeLany JP et al. Long-term calorie restriction reduces energy expenditure in aging monkeys. J of Gerontol A Biol Sci Med Sci 1999; 54:B5–B11.

    CAS  Google Scholar 

  78. Hansen BC, Bodkin NL, Ortmeyer HK. Calorie restriction in non human primates: Mechanisms of reduced morbidity and mortality. Toxicol Sci 1999; 52S:56–60.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Obesity, Diabetes, and Aging Research Center, University of South Florida College of Medicine, Tampa, FL

    Barbara Caleen Hansen PhD (Professor of Internal Medicine and Pediatrics, Director)

Authors
  1. Barbara Caleen Hansen PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Obesity, Diabetes, and Aging Research Center, University of South Florida College of Medicine, Tampa, FL

    Barbara Caleen Hansen PhD (Professor of Internal Medicine and Pediatrics Director) (Professor of Internal Medicine and Pediatrics Director)

  2. Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA

    George A. Bray MD (Boyd Professor) (Boyd Professor)

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Hansen, B.C. (2008). Chronomics of the Metabolic Syndrome. In: Hansen, B.C., Bray, G.A. (eds) The Metabolic Syndrome. Contemporary Endocrinology. Humana Press. https://doi.org/10.1007/978-1-60327-116-5_19

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-116-5_19

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-738-9

  • Online ISBN: 978-1-60327-116-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation